BACKGROUND: We have shown that the cardiotonic steroid marinobufagenin (MBG) is elevated in clinical and experimental renal disease, and significantly contributes to the development of experimental uremic cardiomyopathy induced by removal of five-sixths of the kidney (5/6 nephrectomy; PNx) in the rat. We have demonstrated that both active and passive immunization against MBG with an anti-MBG monoclonal antibody (mAb 3E9) significantly attenuated cardiac fibrosis following PNx. In the present study we sought to determine whether the use of mAb 3E9 could improve renal function following PNx. METHODS: Sprague-Dawley rats were treated with either mAb 3E9 or with DigiFab (an affinity-purified anti-digoxin antibody formerly named Digibind) during the fourth week after PNx. Sham-operated animals and PNx animals treated with an IgG antibody served as controls. Plasma, urine, and renal tissue were collected at the completion of the study to determine the effects of antibody treatment on renal function. RESULTS: In PNx rats, treatments with mAb 3E9 and DigiFab, respectively, significantly reduced plasma creatinine, improved creatinine clearance, and reduced proteinuria below the values of these three measures in IgG-treated PNx controls. Additionally, treatment with mAb 3E9 and DigiFab significantly reduced renal fibrosis as measured with Western blotting and Sirius red/Fast green staining. CONCLUSIONS: Passive immunization against MBG significantly improved renal function and markedly reduced renal fibrosis following the experimental induction of renal disease. The work in the study reported here adds to a growing body of knowledge implicating MBG in the development of chronic renal disease. Passive immunization against cardiotonic steroids may serve as a promising treatment for chronic renal disease.
BACKGROUND: We have shown that the cardiotonic steroid marinobufagenin (MBG) is elevated in clinical and experimental renal disease, and significantly contributes to the development of experimental uremic cardiomyopathy induced by removal of five-sixths of the kidney (5/6 nephrectomy; PNx) in the rat. We have demonstrated that both active and passive immunization against MBG with an anti-MBG monoclonal antibody (mAb 3E9) significantly attenuated cardiac fibrosis following PNx. In the present study we sought to determine whether the use of mAb 3E9 could improve renal function following PNx. METHODS:Sprague-Dawley rats were treated with either mAb 3E9 or with DigiFab (an affinity-purified anti-digoxin antibody formerly named Digibind) during the fourth week after PNx. Sham-operated animals and PNx animals treated with an IgG antibody served as controls. Plasma, urine, and renal tissue were collected at the completion of the study to determine the effects of antibody treatment on renal function. RESULTS: In PNx rats, treatments with mAb 3E9 and DigiFab, respectively, significantly reduced plasma creatinine, improved creatinine clearance, and reduced proteinuria below the values of these three measures in IgG-treated PNx controls. Additionally, treatment with mAb 3E9 and DigiFab significantly reduced renal fibrosis as measured with Western blotting and Sirius red/Fast green staining. CONCLUSIONS: Passive immunization against MBG significantly improved renal function and markedly reduced renal fibrosis following the experimental induction of renal disease. The work in the study reported here adds to a growing body of knowledge implicating MBG in the development of chronic renal disease. Passive immunization against cardiotonic steroids may serve as a promising treatment for chronic renal disease.
Authors: Steven T Haller; David J Kennedy; Amjad Shidyak; George V Budny; Deepak Malhotra; Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov Journal: Am J Hypertens Date: 2012-03-01 Impact factor: 2.689
Authors: Jihad Elkareh; David J Kennedy; Belvadi Yashaswi; Sandeep Vetteth; Amjad Shidyak; Eric G R Kim; Sleiman Smaili; Sankaridrug M Periyasamy; Imad M Hariri; Larisa Fedorova; Jiang Liu; Liang Wu; M Bashar Kahaleh; Zijian Xie; Deepak Malhotra; Olga V Fedorova; Vladimir A Kashkin; Alexei Y Bagrov; Joseph I Shapiro Journal: Hypertension Date: 2006-12-04 Impact factor: 10.190
Authors: David J Kennedy; Sandeep Vetteth; Sankaridrug M Periyasamy; Mohamed Kanj; Larisa Fedorova; Samer Khouri; M Bashar Kahaleh; Zijian Xie; Deepak Malhotra; Nikolai I Kolodkin; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov; Joseph I Shapiro Journal: Hypertension Date: 2006-01-30 Impact factor: 10.190
Authors: Larisa V Fedorova; Vanamala Raju; Nasser El-Okdi; Amjad Shidyak; David J Kennedy; Sandeep Vetteth; David R Giovannucci; Alexei Y Bagrov; Olga V Fedorova; Joseph I Shapiro; Deepak Malhotra Journal: Am J Physiol Renal Physiol Date: 2009-01-28
Authors: Fatimah K Khalaf; Prabhatchandra Dube; Andrew L Kleinhenz; Deepak Malhotra; Amira Gohara; Christopher A Drummond; Jiang Tian; Steven T Haller; Zijian Xie; David J Kennedy Journal: Hypertension Date: 2019-05-28 Impact factor: 10.190
Authors: Rafael Kramann; Johanna Erpenbeck; Rebekka K Schneider; Anna B Röhl; Marc Hein; Vincent M Brandenburg; Merel van Diepen; Friedo Dekker; Nicolaus Marx; Jürgen Floege; Michael Becker; Georg Schlieper Journal: J Am Soc Nephrol Date: 2014-04-03 Impact factor: 10.121
Authors: Christopher A Drummond; Laura E Crotty Alexander; Steven T Haller; Xiaoming Fan; Jeffrey X Xie; David J Kennedy; Jiang Liu; Yanling Yan; Dawn-Alita Hernandez; Denzil P Mathew; Christopher J Cooper; Joseph I Shapiro; Jiang Tian Journal: Physiol Genomics Date: 2016-10-27 Impact factor: 3.107
Authors: Steven T Haller; Sivarajan Kumarasamy; David A Folt; Leah M Wuescher; Stanislaw Stepkowski; Manish Karamchandani; Harshal Waghulde; Blair Mell; Muhammad Chaudhry; Kyle Maxwell; Siddhi Upadhyaya; Christopher A Drummond; Jiang Tian; Wanda E Filipiak; Thomas L Saunders; Joseph I Shapiro; Bina Joe; Christopher J Cooper Journal: Kidney Int Date: 2016-09-28 Impact factor: 10.612
Authors: Christopher A Drummond; Michael C Hill; Huilin Shi; Xiaoming Fan; Jeffrey X Xie; Steven T Haller; David J Kennedy; Jiang Liu; Michael R Garrett; Zijian Xie; Christopher J Cooper; Joseph I Shapiro; Jiang Tian Journal: Physiol Genomics Date: 2015-12-23 Impact factor: 3.107
Authors: Grzegorz Piecha; Agata Kujawa-Szewieczek; Piotr Kuczera; Katarzyna Skiba; Ewelina Sikora-Grabka; Andrzej Więcek Journal: Am J Physiol Renal Physiol Date: 2018-07-25